Denali Therapeutics
DNLI
214 hedge funds and large institutions have $4.28B invested in Denali Therapeutics in 2021 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 81 increasing their positions, 65 reducing their positions, and 31 closing their positions.
139% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $5.19M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
25% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 65
19% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 31
3.18% more ownership
Funds ownership: 66.56% → 69.74% (+3.2%)
2% more funds holding
Funds holding: 210 → 214 (+4)
32% less capital invested
Capital invested by funds: $6.32B → $4.28B (-$2.04B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pathway Capital Management
Irvine,
California
|
+$57.1M |
| 2 |
Temasek Holdings
Singapore
|
+$54.1M |
| 3 |
BlackRock
New York
|
+$29.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$26.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
Euclidean Capital
New York
|
-$25.4M |
| 2 |
CM
Crestline Management
Fort Worth,
Texas
|
-$24.3M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$20.4M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$18.9M |
| 5 |
Jennison Associates
New York
|
-$8.23M |
DNLI Hedge Fund Activity: Q3 2021 in Review
214 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q3 2021, worth a combined $4.28B — down 32% from $6.32B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new DNLI positions and 31 closed out — a net gain of 6 holders — while 81 added to existing stakes and 65 trimmed.
The largest buyer was Pathway Capital Management, opening a new position worth an estimated $57.1M. The largest seller was Euclidean Capital, exiting entirely with an estimated $25.4M sold.
- 214 institutional investors held Denali Therapeutics (DNLI) as of Q3 2021, up from 210 in Q2 2021.
- Funds reported $4.28B of Denali Therapeutics stock for Q3 2021, down 32% quarter-over-quarter.
- 37 funds opened new Denali Therapeutics positions in Q3 2021 and 31 closed out, a net change of +6 holders.
- The largest Denali Therapeutics buyer in Q3 2021 was Pathway Capital Management, an estimated $57.1M added.
- The largest Denali Therapeutics seller in Q3 2021 was Euclidean Capital, an estimated $25.4M sold.
Based on aggregated 13F filings for Q3 2021.